20
Cat No. | Product Name | Synonyms | Targets |
---|---|---|---|
T10741 | CDK9-IN-1 | CDK | |
CDK9-IN-1 is a novel, selective CDK9 inhibitor for the treatment of HIV infection (IC50: 39 nM for CDK9/CycT1). | |||
T62746 | EGFR/HER2/CDK9-IN-1 | ||
EGFR/HER2/CDK9-IN-1 (Compound 4) is a potent EGFR/HER2/CDK9 inhibitor with IC50 values of 90.17, 131.39 and 67.04 nM. EGFR/HER2/CDK9-IN-1 exhibits significant anti-tumour effects. | |||
T63851 | CDK9/10/GSK3β-IN-1 | ||
CDK9/10/GSK3β-IN-1 is a kinase inhibitor (Flavopiridol analogue) that effectively inhibits HsGSK3β, HsCDK9/CyclinT, HsCDK5/p25 and HsCDK2/CyclinA with IC50 values of 59 nM, 64 nM, 1.093 μM and 1.725 μM, respectively. CDK... | |||
T82758 | CDK9-Cyclin T1 PPI-IN-1 | CDK | |
CDK9-Cyclin T1 PPI-IN-1 (Compound B19) is a selective inhibitor of the CDK9-Cyclin T1 protein-protein interaction (PPI), suppressing cell proliferation in TNBC MDA-MB-231 cells with an IC50 of 0.044 μM and inducing apopt... | |||
T9632 | CDK9-IN-30 | HIV Protease | |
CDK9-IN-30 is one of the Tat peptide derivatives and inhibits HIV-1 long terminal repeat-activated transcription. | |||
T10096L | Voruciclib | CDK | |
Voruciclib is an orally active and selective CDK inhibitor (Ki: 0.626 nM-9.1 nM). Voruciclib represses the expression of MCL-1 in multiple models of diffuse large B-cell lymphoma. Voruciclib effectively blocks CDK9, the ... | |||
T23840 | BUR1 | BMP upregulator-1,BMP upregulator 1,BUR 1,BUR-1 | CDK |
BUR1 is a selective BMP upregulator that acts by increasing the expression of Inhibitor of DNA binding 1 and inducing BMP2 and PTGS2 expression. | |||
T10743 | CDK9-IN-11 | CDK | |
CDK9-IN-11 is a potent CDK9 inhibitor that is the ligand for the PROTAC CDK9 Degrader-1 [1]. | |||
T39997 | PROTAC CDK9 ligand-1 | PROTAC CDK9 ligand-1 | |
PROTAC CDK9 ligand-1 is a CDK9 ligand that can be used in the synthesis of PROTACs. | |||
T79631 | CDK9-IN-26 | CDK | |
CDK9-IN-26, also known as compound 1, is a potent inhibitor of Cyclin-Dependent Kinase 9 (CDK9) with an IC50 value of 0.18 μM.[1] | |||
T79037 | CDK9-IN-23 | CDK | |
CDK9-IN-23 (Example 4) is a potent inhibitor of CDK9, exhibiting an IC50 value of less than 20 nM [1]. | |||
T79704 | CDK9-IN-28 | CDK | |
PROTAC CDK9/CycT1 Degrader-1 (compounds 10), a potent CDK9 inhibitor, serves as a target protein ligand for PROTAC synthesis. Exhibiting substantial anti-proliferative activity in solid tumors [1], this compound is instr... | |||
T36744 | CDK9 Antagonist-1 | CDK9 Antagonist-1 | |
CDK9 Antagonist-1 (compounds 11c) is a potent and selective CDK9 degrader based on PROTAC, with an IC50 of 17 μM in MCF-7 cell lines. Natural product Wogonin binds ubiquitin E3 ligase cereblon (CRBN) via a linker to form... | |||
T78928 | PROTAC CDK9 degrader-8 | PROTACs | |
PROTAC CDK9 Degrader-8 (Compound 21) is a potent degrader of CDK9 with an IC50 of 0.01 μM, utilized in cancer research [1]. | |||
T82757 | CDK9-IN-29 | CDK | |
CDK9-IN-29 (compound Z11) is a potent inhibitor of CDK9, exhibiting high kinase selectivity and an IC50 value of 3.20 nM. It effectively hinders cell proliferation and induces apoptosis [1]. | |||
T79354 | CDK9-IN-24 | CDK | |
CDK9-IN-24 (compound 21a) is a potent and selective inhibitor of CDK9 that exhibits a pronounced inhibitory impact on tumor proliferation. It impedes cell growth and triggers apoptosis via the downregulation of Mcl-1 and... | |||
T10739 | CDK8/19-IN-1 | CDK | |
CDK8/19-IN-1 is a selective and oral bioavailable CDK8/19 dual inhibitor (IC50s: 0.46 nM, 0.99 nM, and 270 nM for CDK8, CDK19, and CDK9). | |||
T36743 | CDK7/9 tide | ||
CDK7/9 tide is peptide substrate for CDK7 or CDK9[1]. [1]. Robert T, et, al. Development of a CDK10/CycM in vitro Kinase Screening Assay and Identification of First Small-Molecule Inhibitors. Front Chem. 2020 Feb 27; 8:1... | |||
T79367 | CDK9-IN-27 | CDK | |
CDK9-IN-27 (Compound 6a), a CDK9 inhibitor with an IC50 of 0.424 μM, induces apoptosis and S-phase cell cycle arrest. It exhibits cytotoxicity against HepG2, HCT-116, and MCF-7 cell lines, with IC50 values ranging from 1... | |||
T14915 | CDK12-IN-E9 | CDK | |
CDK12-IN-E9 is a potent and selective covalent CDK12 inhibitor and non-covalent CDK9 inhibitor while avoiding ABC transporter-mediated efflux. It has a weak binding ability to CDK7/CyclinH complex (IC50> 1 μM). |